Robert Nelson, MD
Psychiatry · Wyomissing, PANPI 1972696037
Payments from drug & device makers
Across 2,745 payments — averaging $787.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$472K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$459K
- Otsuka America Pharmaceutical, Inc.$412K
- Teva Pharmaceuticals USA, Inc.$397K
- Axsome Therapeutics, Inc.$169K
- E.r. Squibb & Sons, L.L.C.$159K
- plus $93K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 665 | $472,231 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 522 | $459,394 |
| Otsuka America Pharmaceutical, Inc. | 578 | $411,520 |
| Teva Pharmaceuticals USA, Inc. | 336 | $396,958 |
| Axsome Therapeutics, Inc. | 173 | $168,675 |
| E.r. Squibb & Sons, L.L.C. | 183 | $159,161 |
| Sunovion Pharmaceuticals Inc. | 78 | $51,508 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 16 | $21,592 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $15,139 |
| Eli Lilly | 3 | $1,900 |
| Lundbeck LLC | 29 | $585 |
| AbbVie(2 entities) | 36 | $553 |
| Neurocrine Biosciences, Inc. | 20 | $465 |
| Vanda Pharmaceuticals Inc. | 14 | $311 |
| Ironshore Pharmaceuticals Inc. | 8 | $185 |
| Johnson & Johnson | 9 | $156 |
| Almatica Pharma LLC | 5 | $119 |
| Corium, LLC | 5 | $105 |
| Shire North American Group Inc | 6 | $92 |
| Acadia Pharmaceuticals Inc | 6 | $85 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Merck | 2 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $43 |
| Vertical Pharmaceuticals, LLC | 2 | $42 |
| MDD US Operations, LLC | 1 | $32 |
| Sage Therapeutics, LLC | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
How this compares
$2,161,009 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Wyomissing
- John TimkoWyomissing$152K
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.